Oh, Sun Jung
Tashjian, Vartan C.
Mirocha, James
Nagar, Menachem
Mathur, Ruchi
Lin, Eugenia
Chua, Kathleen Shari
Rezaie, Ali
Pimentel, Mark
Pichetshote, Nipaporn http://orcid.org/0000-0002-2186-6984
Article History
Received: 17 April 2018
Accepted: 24 September 2018
First Online: 15 October 2018
Compliance with ethical standards
:
: Cedars-Sinai has licensing agreements with Salix Pharmaceuticals, Naia Pharmaceuticals, Gemelli Biotech, Inc., and Synthetic Biologics Inc. Mark Pimentel is a consultant for Salix Pharmaceuticals, Naia Pharmaceuticals, Synthetic Biologics Inc., Shire, and US Medical, is a board member of Gemelli Biotech and has received research funding from Salix Pharmaceuticals and Synthetic Biologics Inc. Ruchi Mathur is a board member of Gemelli Biotech and has received research funding from Valeant Pharmaceuticals and the American Diabetes Association. Ali Rezaie has received speaker and consultant fees from Commonwealth Laboratories, Actavis, and Salix Pharmaceuticals, and has received research funding from Valeant Pharmaceuticals, the American College of Gastroenterology, and the Kenneth Rainin Foundation. The remaining authors have no conflicts to disclose.